PubMed: Cannabinoids for skin diseases and hair regrowth
J Cosmet Dermatol. 2021 Aug 7. doi: 10.1111/jocd.14352. Online ahead of print.
The use of cannabis for skin diseases and hair regrowth is at the preliminary stage.
LEGALIZATION: Many countries have approved cannabis for medical use; however, four countries Canada, Uruguay, South Africa, and Georgia have legalized it for both medical and recreational purposes.
THE ENDOCANNABINOID SYSTEM: The endocannabinoid system may maintain skin homeostasis; two notable endocannabinoids include 2-Arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA).
ROUTES OF ADMINISTRATION AND PHARMACOKINETICS: Topical cannabinoids can avoid the first-pass metabolism and reduce respiratory side effects; however, the high hydrophobicity of cannabinoids may hinder percutaneous absorption.
SKIN DISORDERS AND HAIR GROWTH: Human clinical studies suggest that cannabinoids may be used in eczema, acne, pruritus, and systemic sclerosis treatment. Cannabidiol (CBD) may enhance hair growth via multiple mechanisms.
SAFETY: Topical cannabis may cause mild side effects such as pruritus, burning, erythema, and stinging; they are relatively safer than inhalation and oral cannabis. Cannabis use may be associated with allergic symptoms and reduced immune response to live vaccination.
CANNABINOIDS IN PRACTICE: Despite growing interest, dermatologists should be cautious prescribing cannabinoids due to insufficient clinical data on both efficacy and safety.
#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34363728/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210808065910&v=2.14.5 August 7, 2021 10:00 am